Clean Copy of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(i)

1. (Amended) A drug delivery composition for nasal administration comprising ICAM-1 and a bioadhesive material, wherein the bioadhesive material is in a liquid formulation comprising a polymeric material, wherein the ICAM-1 is present in the liquid formulation in a concentration between about 0.01 and 20% by weight per volume, and wherein the composition delivers to the nasal cavity an antivirally effective amount of ICAM-1.

2. (Amended) The drug delivery composition according to claim 1 wherein the bioadhesive material is a chitosan solution.

3. (Amended) The drug delivery composition according to claim 2 wherein the chitosan is in the solution in a concentration in the range of 0.2 - 2.0% w/v.

4. (Amended) The drug delivery composition according to claim 2 wherein the ICAM-1 is present in the chitosan solution in a concentration in the range of 0.2 to 5% w/v.

5. (Amended) A drug delivery composition for nasal administration comprising ICAM-1 and a bioadhesive material in a dry powder formulation, wherein the bioadhesive material is a plurality of microspheres made from a material selected from the group consisting of starch, chitosan, gelatin, hyaluronic acid, alginate, and gellan, wherein the ICAM-1 content of the formulation is between about 0.1 and 50% by weight, and wherein the

composition delivers to the nasal cavity an antivirally effective amount of ICAM-1.

7. (Amended) The drug delivery composition according to claim 5 wherein the ICAM-1 is present in an amount of 1% to 20% w/w of the microspheres.

9. (Amended) The drug delivery composition according to claim 1 wherein the polymeric material is selected from the group consisting of gellan gum, alginate, welan, xanthan, and rhamsan.

10. (Amended) The drug delivery composition according to claim 1 wherein the polymeric material is provided in a concentration of 0.1% to 5% w/v.

11. (Amended) The drug delivery composition according to claim 8 wherein the ICAM-1 is present in the formulation in an amount of 0.2% to 5% w/v.

12. (Amended) A method of delivering ICAM-1 to the nasal cavity to increase its effectiveness therein comprising

administering the ICAM-1 in a drug delivery composition additionally comprising a bioadhesive material, wherein the bioadhesive material is in a liquid formulation comprising a polymeric material or is in a dry powder formulation comprising a plurality of microspheres made from a material selected from the group consisting of starch, chitosan, gelatin, hyaluronic acid,

alginate, and gellan, and wherein the composition delivers to the nasal cavity an antivirally effective amount of ICAM-1.

ATL1 #491560 v1